Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer: A Multicenter, Single-Arm Study

NCT07831330 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT07831330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07831330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer: A Multicenter, Single-Arm Study
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 5, 2026
Completion date
June 30, 2029
Enrollment
59 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

albumin-bound paclitaxel (ii), first-line, gemcitabine, metastatic pancreatic adenocarcinoma